<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-78899</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Matrix metalloproteinase 9 polyphormisms in the diagnosis of prostate cancer. A preliminary experience</dc:title>
<dc:description xml:lang="en">Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer. So far there are no studies in the literature analysing the link between polymorphisms Q279R, P574R and -1562 C/T of MMP-9 and prostate cancer.OBJECTIVES: To establish the presence of the MMP-9´s gene polymorphisms (Q279R, P574R and -1562 C/T)in relation to results of prostate biopsy, PSA values and Gleason score.METHODS: Hospital cohort of 100 patients with suspected prostate cancer, subjected to prostate biopsy, in whom the MMP-9 polymorphisms (Q279R, P574R and -1562 C/T) were analysed using the PCR-RLFP technique.RESULTS: No statistically significant differences were found in the presence of the Q279R, P574R and -1562 C/T polymorphisms in terms of prostate biopsy results (p = 0.264, p = 0.406, p = 0.860, respectively), or Gleason score (p = 0.373, p = 0.367, p = 0.476). Comparing the genotypes of the Q279R, P574R and -1562 C/T polymorphisms resulting from prostate biopsy, , using subgroups according to PSA values, no statistically significant differences were found either (p = 0.332 y p = 0.393, respectively ). However, statistically significant differences were found when comparing the genotypes of the -1562 C/T polymorphism of the MMP-9 in patients showing positive biopsy for malignant tumour in comparison to a negative biopsy for a malignant tumour in the subgroup of patients with PSA &gt; 10 ng/ml (p=0.049). The joint analysis of the three MMP-9 polymorphisms, using logistical regression study did not reveal any statistically significant differences as far as the risk of developing prostate cancer is concerned based on the presence of the Q279R, P574R and -1562 C/T polymorphisms.CONCLUSION: The Q279R, P574R and -1562 C/T polymorphisms are not linked with the aggressiveness in prostate cancer, neither they are linked to the risk of suffering prostate cancer(AU)</dc:description>
<dc:creator>Tardón, Adonina</dc:creator>
<dc:creator>Muruamendiaraz Fernández, Valentín</dc:creator>
<dc:creator>González Arriaga, Patricia</dc:creator>
<dc:creator>Fernandez Samoano, Ana</dc:creator>
<dc:creator>Gil Ugarteburu, Rodrigo</dc:creator>
<dc:creator>Rivas del Fresno, Manuel</dc:creator>
<dc:creator>González Rodríguez, Iván</dc:creator>
<dc:creator>López Cima, Felicitas</dc:creator>
<dc:creator>Fernández García, Isabel</dc:creator>
<dc:creator>Benito García, Priscila</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los polimorfismos Q279R, P574R y -1562 C/T en el gen de la MMP-9 se han relacionado con el riesgo de padecer cáncer y con la agresividad tumoral de varios tipos de cánceres. Hasta ahora no existen estudios en la literatura que analicen la asociación de los polimorfismos Q279R, P574R y -1562 C/T de la MMP-9 con el cáncer prostático.OBJETIVOS: Determinar las diferencias de presencia de los polimorfismos en el gen de la MMP-9 (Q279R, P574R y -1562 C/T) en función del resultado de la biopsia prostática, de las cifras del PSA y el grado histológico Gleason.MÉTODOS: Se trata de una cohorte de base hospitalaria que incluye 100 pacientes con sospecha de carcinoma prostático, sometidos a biopsia prostática, a los que se determinaron los polimorfismos de la MMP-9 (Q279R, P574R y -1562 C/T) mediante la técnica de PCR-RFLP.RESULTADOS: No se encontraron diferencias estadísticamente significativas en la presencia de los polimorfismos Q279R, P574R y -1562 C/T de la MMP-9, en función del resultado de la biopsia prostática (p = 0,264, p = 0,406, p = 0,860, respectivamente), ni en función del grado Gleason (p = 0,373, p = 0,367, p = 0,476). Al comparar los distintos genotipos de los polimorfismos Q279R y P574R de la MMP-9 en función del resultado de la biopsia prostática, haciendo subgrupos según las cifras del PSA, tampoco se encontraron diferencias estadísticamente significativas (p = 0,332 y p = 0,393, respectivamente). Se encontraron diferencias estadísticamente significativas al comparar los distintos genotipos del polimorfismo -1562 C/T de la MMP-9, en pacientes con biopsia positiva para tumor maligno respecto a biopsia negativa para tumor maligno en el subgrupo de pacientes de PSA &gt; 10 ng/ml (p = 0,049)...(AU)</dc:description>
<dc:source>Arch Esp Urol;63(2): 125-132, mar. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-78899</dc:identifier>
<dc:title xml:lang="es">Polimorfismo de la metaloproteasa de matriz 9 (MMO-9) en el diagnostico del carcinoma prostático. Experiencia preliminar</dc:title>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d11910^s22009</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d34537^s22074</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d38178</dc:subject>
<dc:subject>^d11914^s22053</dc:subject>
<dc:subject>^d11910^s22053</dc:subject>
<dc:subject>^d11910^s22010</dc:subject>
<dc:subject>^d11911^s22066</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d11914^s22009</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d11914^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201003</dc:date>
</metadata>
</record>
</ibecs-document>
